ADBE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Adobe Inc. · Technology
$248.16
+45.0% upside to fair value
High Conviction
Grade B
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
PFE |
| Current Price |
$248.16 |
$26.33 |
| Fair Value Estimate |
$359.82 |
$33.85 |
| Upside to Fair Value |
+45.0%
|
+28.6%
|
| Market Cap |
$101.2B |
$149.8B |
| Forward P/E |
14.1x
|
19.3x
|
| EV / EBITDA |
—
|
12.9x
|
| Price / Sales |
4.1x
|
2.4x
|
| Price / FCF |
9.8x
|
16.5x
|
| Revenue Growth YoY |
+3.3%
|
-1.2%
|
| Gross Margin |
89.1%
|
70.3%
|
| Operating Margin |
36.6%
|
24.7%
|
| Return on Equity |
62.3%
|
8.7%
|
| Dividend Yield |
— |
0% |
| FCF Yield |
10.2%
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
ADBE |
PFE |
| Zone Low |
$269.87 |
$25.39 |
| Zone High |
$305.85 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|